Floatz logo

LEUPROLIDE

Androgen Deprivation Therapy

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápicprotein_peptidePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Androgen Deprivation Therapy cohort.

Asset / SponsorPhaseRating
Zoladex
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase 3B
Casodex
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase 3B
Fezolinetant
Shehzad Basaria, M.D.
Phase 2CCC
Enzalutamide
University of Oklahoma
Phase 1CC
Relugolix
University of Oklahoma
Phase 1CC

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →